Bibliography

[1] US Department of Health and Human Services: "Guidelines for the Use of Antiretroviral Agents in HIV-infected Adults and Adolescents", AIDSinfo, April, 2005, http://www.aidsinfo.nih.gov/.

[2] Altfeld M., Rosenburg E.S., Shankarappa R., Mukherjee J., *et al.* "Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection," *J Exp Med*, **193(2)**, pp. 169-180, 2001.

[3] Concord Coordinating Committee, "MRC /ANRS randomized double-blind controlled trial of immediate and deferred AZT in symptom free HIV infection", *Lancet*, **343**, pp. 871-881, 1994.

[4] Hogg R.S., Yip B., Chan K., Wood E., *et al.*, "Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy," *JAMA*, **286(20)**, pp. 2568-2577, 2001.

[5] Hogg R.S., Yip B., Wood E., Chan K., Craib K.J.P., O'Shaughnessy M.V. and Montaner J.S.G. "Diminished effectiveness of antiretroviral therapy among patients initiating therapy with $CD4^+$ cell counts below $200/mm^3$," *Proc. 8th Conference on Retroviruses and Opportunistic Infections*, Chicago, USA, 4 –8 Feb 2001.

[6] Kaplan J., D. Hanson, J. Karon, D. Cohn, M. Thompson, S. Buskin, P. Fleming, and M. Dworkin, "Late initiation of antiretroviral therapy (at $CD4^+$ lymphocyte count < 200 cells/mL) is associated with increased risk of death," *Proc. 8th Conference on Retroviruses and Opportunistic Infections*, Chicago, USA, 4 –8 Feb 2001.

[7] Kirschner D. and Webb G.F. "A model for treatment strategy in the chemotherapy of AIDS", *Bull. Math. Biol.*, **58(2)**, pp. 367-390, 1996.

[8] Opravil M., B. Ledergerber, H. Furrer, S. Gallant, B. Hirschel, F. Meienberg, T. Wagels, E. Bernasconi, M. Rickenbach, R. Weberand The Swiss HIV Cohort Study

(SHCS). "Clinical benefit of early initiation of HAART in patients with asymptomatic HIV infection and CD4$^+$ Counts $> 350/\text{mm}^3$". *Proc. 8th Conference on Retroviruses and Opportunistic Infections*, Chicago, USA, 4-8 Feb. 2001.

[9] Phillips A.N., Staszewski S., Weber R., Kirk O., *et al.* "HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load" *JAMA*, **286(20)**, pp. 2560-2567, 2001.

[10] Plana M., Garcia F., Gallart T., Tortajada C., *et al.* "Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection," *AIDS*, pp. -, 2000.

[11] Pomerantz R.J. "Initiating antiretroviral therapy during HIV infection : confusion and clarity", *JAMA* **286(20)**, pp. 2597-2599, 2001.

[12] Sterling T.R., Chaisson R.E., Bartlett J.G. and Moore R.D. "CD4$^+$ Lymphocyte level is better than HIV-1 plasma viral load in determining when to initiate HAART," *Proc. 8th Conference on Retroviruses and Opportunistic Infections*, Chicago, USA, 4-8 Feb 2001.

[13] Lisziewicz J., Rosenburg E., Lieberman J., Jessen H., *et al.* "Control of HIV despite the discontinuation of antiretroviral therapy", *New Engl. J. Med.*, **340(21)**, pp. 1683-1694, 1999.

[14] Lori F., Maserati R., Foli A., Siminari E., Timpone J. and Lisziewicz J. "Structured treatment interruptions to control HIV-1 infection", *Lancet*, **355**, pp. 287-288, 2000.

[15] Ortiz G.M., Nixon D.F., Trkola A., Binley J., *et al.* "HIV-1 specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy", *J Clin. Invest.*, **104**, pp. R13-R18, 1999.

[16] Rosenburg E.S., Altfeld M., Poon S.H., Phillips M., *et al.* "Immune control of HIV-1 after early treatment of acute infection" *Nature*, **407**, pp. 523-526, 2000.

[17] Wodarz D., Arnaout R., Nowak M.A. and Lifson J. "Transient antiretroviral treatment during acute simian immunodeficiency virus infection facilitates long-term control of the virus", *Philos Trans Royal Soc Lond B Biol Sci*, **355**, pp. 1021-1029, 2000.

[18] Wodarz D. and Nowak M.A. "Specific therapy regimens could lead to long-term immunologic control of HIV," *PNAS*, **96(25)**, pp. 14464-14469, 1999.

[19] Abbas U.L. and Mellors J.W. "Interruption of antiretroviral therapy to augment immune control of chronic HIV-1 infection: risk without reward," *Proc Natl Acad Sci USA*, **99(21)**, pp. 13377-13378, 2002.

[20] Ananworanich J., Nuesch R., Braz M.L., Chetchotisakd P., *et al.* "Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial" *AIDS*, **17(15)**, pp. F33-37, 2003.

[21] Oxenius A. and Hirschel B. "Structured treatment interruptions in HIV infection: benefit or disappointment?", *Anti-Infect. Ther.*, **1(1)**, pp. 129-139, 2003.

[22] Bean P. "Role of viral load blips, drug boosting, and therapeutic holidays in HIV patient management", *American Clin. Lab.*, **20(8)**, pp. 11-13, 2001.

[23] Di Mascio M., Markowitz M., Louie M., Hogan C., *et al*, "Viral blip dynamics during highly active antiretroviral therapy,", *J. Virology*, **77**, pp. 12165-12172. 2003.

[24] Havlir D.V., Bassett R., Levitan D., *et al.*, "Prevalence and predictive value of intermittent viremia with combination HIV therapy", *J. American Med. Ass.*; **286(2)**, pp. 171-179, 2001.

[25] Moore A.L., Youle M., Lipman M., Cozzi-Lepri A., Lampe F., *et al.* "Raised viral load in patients with viral suppression on highly active antiretroviral therapy: transient increase or treatment failure?", *AIDS*; **16(4)**, pp. 615-618, 2002.

[26] Embretson J., Zupancic M., Beneke J., Till M., Wolinski S., Ribas J.L., *et al.* "Analysis of HIV infected tissues by amplification and *in situ* hybridization reveals latent and permissive infections at single-cell resolution". *Proc. Natl. Acad. Sci.*, **90**, pp. 357-61, 1993.

[27] Finzi D., Blackson J., Siliciano J., Margolick J., *et al.* "Latent infection of $CD4^+$ T cells provides a mechanism for lifelong persistence of HIV-1, even on patients on effective combination therapy", *Nature Med.*, **5(5)**, pp. 512-517, 1999.

[28] Furtado M.R., Callaway D.S., Phair J.P., Kunstman K.J., *et al.* "Persistence of HIV-1 transcription in peripheral blood mononuclear cells in patients receiving potent antiretroviral therapy", *New England J. Med.*, **340(21)**, pp. 1614-1622, 1999.

[29] Grossman Z., Polis M., Feinberg M.B., Levi I., Jankelevich S., Yarchoan R., *et al.* "Ongoing dissemination during HAART", *Nature Med.*, **5**, pp. 1099-104, 1999.

[30] Natarajan V., Bosche M., Metcalf J.A., Ward D.J., Lane H.C. and Kovacs J.A. "HIV-1 replicates in patients with undetectable plasma virus receiving HAART", *Lancet*, **353**, pp. 119-120, 1999.

[31] Ngo-Giang-Huong N., Deveau C., Da Silva I., Pellegrin I., *et al.* "Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapy", *AIDS*, **15**, pp. 665-673, 2001.

[32] Wong J.K., Hezareh M., Gunthard H.F., Havlir D.V., Ignacio C.C., Spina C.A. and Richman D.D. "Recovery of replication-competent HIV despite prolonged suppression of plasma viremia," *Science*, **278**, 1291-1295, 1997.

[33] Zhang L., Ramratnam B., Tenner-Racz K., He Y., Vesanen M., Lewin S., *et al.* "Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy", *New Eng. J. Med.*, **340(21)**, pp. 1605-1613, 1999.

[34] Aweeka F., Jayewardene A., Staprans S., *et al.* "Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1 infected patients with and without AIDS dementia complex". *J AIDS Hum. Retrovir.* **20**, pp. 39-43, 1999.

[35] Kepler T.B. and Perelson A.S. "Drug concentration heterogeneity facilitates the evolution of drug resistance", *Proc. Natl. Acad. Sci. USA,* **95**, pp. 11514-11519, 1998.

[36] Mansky L.M., Le Rouzic E., Benichou S. and Gajary L.C. "Influence of reverse transcriptase variants, drugs and Vpr on human immunodeficiency virus type 1 mutant frequencies," *J. Virology*, **77(3)**, pp. 2071-2080, 2003.

[37] Perno C-F., Newcomb F.M., Davis D.A., Aquaro S., *et al.* "Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus." *J. Infect. Diseases*, **178**, pp. 413-422, 1998.

[38] Taylor S., Back D., Workman J., *et al.* "Poor penetration of the male genital tract by HIV-1 protease inhibitors". *AIDS*, **13**, pp. 859-860, 1999.

[39] Chun T-W., Engel D., Berrey M.M., Shea T., Corey L. and Fauci A.S. "Early establishment of a pool of latently infected, resting $CD4^+$ T cells during primary HIV-1 infection", *Proc. Natl. Acad. Scie. USA*, **95**, pp. 8869-8873, 1998.

[40] Finzi D., Hermankova M., Pierson T., Carruth L.M., Buck C., *et al.* "Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy", *Science*, **278**, pp. 1295-1300, 1997.

[41] Roden D.M. and George A.L. Jr. "The genetic basis of variability in drug responses," *Nature Revs. - Drug Discovery*, **1**, pp. 37-44, 2002.

[42] "Guest Editorial: Special Issue on Systems and Control Problems in Medicine," *IEEE Trans. AC*, **43(6)**, pp. 763-764, 1998.

[43] Jeffrey A.M., Xia X. and Craig I.K. "When to initiate HIV therapy : a control theoretic approach," *IEEE Trans. BME*, **50(11)**, pp. 1213-1220, 2003.

[44] Ko J.H., Kim W.H., and Chung C.C. "Optimized structured treatment interruption for HIV therapy and its performance analysis on controllability", *IEEE Trans BME*, **53(3)**, pp. 380-386, 2006

[45] Kim J, Kim W.H., Chung H.B., and Chung C.C. "Constant drug dose leading long-term non-progressor for HIV-infected patients with RTI and PI," *Proc. IEEE Conf. on Decision and Control and European Control Conf.*, Seville, Spain. pp. 909-916, Dec 12-15 2005.

[46] Alvarez-Ramirez J., Meraz M. and Velasco-Hermandez J.X. "Feedback control of the chemotherapy of HIV", *Int. J. of Bifurc. and Chaos*, **10(9)**, pp. 2207-2219, 2000.

[47] Brandt M.E. and Chen G. "Feedback control of a biodynamical model of HIV-1", *IEEE Trans. BME*, **48(7)**, pp. 754-759, 2001.

[48] Butler S., Kirschner D. and Lenhart S. "Optimal control of chemotherapy affecting the infectivity of HIV", *Advances in Mathematical Populations Dynamics: Molecules, Cells, Man.* World Scientific Publishing, pp. 104-120, 1997.

[49] de Souza J.A.M.F., Caetano M.A.L. and Yoneyama T. "Optimal control theory applied to the anti-viral treatment of AIDS", *Proc.* 39^{th} *IEEE Conf. on Decision and Control,* Sydney, Australia, pp. 4839-4844, 2000.

[50] Kirschner D., Lenhart S. and Serbin S. "Optimal control of the chemotherapy of HIV", *J. Math. Biol.*, **35**, pp. 775-792, 1997.

[51] Wein L.M., Zenios S.A. and Nowak M.A. "Dynamic multidrug therapies for HIV: a control theoretic approach", *J. Theor. Biol.*, **185**, pp. 15-29, 1997.

[52] Shim H., Han S.J., Chung C.C., Nam S.W. and Seo J.H. "Optimal scheduling of drug treatment for HIV infection: continuous dose control and receding horizon control", *International Journal of Control, Automation and Systems*, **1(3)**, pp. 282-288, 2003.

[53] Zurakowski R. and Teel A.R. "A model predictive control based scheduling method for HIV therapy", *J. Theor. Biol.*, **238(2)**, pp. 368-382, 2006.

[54] Chang H.J., Shim H. and Seo J.H. "Control of immune response of HIV infection model by gradual reduction of drug dose", *In proc. 43rd IEEE Conf. Decision and Control*, (Atlantis, Bahamas), pp. 1048-1054, 14-17 December, 2004.

[55] Jeffrey A.M., Xia X. and Craig I.K. "A Model Predictive Control Approach to Drug Dosage Design for HIV Therapy," Submitted: *IEEE Trans. CST*, 2005.

[56] Zhiling T., Ge S.S. and Tong H.L, "Globally stable nonlinear control of HIV-1 systems," *Proc. American Control Conf.*, **(2)**, pp. 1633-1638, 2004.

[57] Jeffrey A.M., Xia X. and Craig I.K. "Structured treatment interruptions: a control mathematical approach to protocol design," Submitted: *J. Process Control*, 2005.

[58] Gumel A.B., Twizell E.H. and Yu P. "Numerical and bifurcation analysis for a population model of HIV chemotherapy", *Math. and Comp. in Sim.*, **54**, pp. 169-181, 2000.

[59] De Leenheer P. and Smith H.L. "Virus dynamics: a global analysis", *SIAM J. App. Math.*, **63(4)**, pp. 1313-1327, 2003.

[60] Jeffrey A.M., Xia X. and Craig I.K. "A viral load time response analysis to antiretroviral therapy," *SAIEE Trans.*, **96(3)**, pp. 234-239, 2005.

[61] Jeffrey A.M. and Xia X. "Identifiability of HIV/AIDS models", In: *Deterministic and Stochastic Models of AIDS Epidemics and HIV Infections with Intervention*, Eds. Wai-Yuan Tan and Hulin Wu. World Scientific Publishing, Singapore. pp. 255-286, 2005.

[62] Xia X. "Estimation of HIV/AIDS parameters," *Automatica*, **39**, 1983-1988, 2003.

[63] Xia X. and Moog C.H. "Identifiability of nonlinear systems with application to HIV/AIDS models," *IEEE Tran. Auto. Contr.*, **48(2)**, pp. 330-336, 2003.

[64] Filter R.A., Xia X. and Gray C.M. "Dynamic HIV/AIDS parameter estimation with application to a vaccine readiness study in Southern Africa", *IEEE Trans. BME.*, **51**, pp. 784-791, 2005.

[65] Ouattara D.A. "Mathematical analysis of the HIV-1 infection : parameter estimation, therapies effectiveness and therapeutical failures", *27th Annual International Conference of the IEEE EMB Society* Shanghai, China, 1-4 September 2005.

[66] Ouattara D.A., Bugnon F., Moog C.H. and Raffi F. "Parameter identification of an HIV/AIDS dynamical model", *13th International Symp. on HIV and Emerging Infectious Diseases*, Toulon, France. pp. 186-192, 2004.

[67] Xia X. "Modelling of HIV infection: vaccine readiness, drug effectiveness and therapeutical failures", In *Proc. Int. Symp. on Advanced Control of Chemical Processes*, Gramado, Brazil. **(2)**, pp. 485-492, 2-5 April, 2006.

[68] Craig I.K., Xia X. and Venter J.W. "Introducing HIV/AIDS education into the electrical engineering curriculum at the University of Pretoria", *IEEE Transactions in. Education*, **47(1)**, pp. 65-73, 2004.

[69] Craig I.K. and Xia X. "Can HIV/AIDS be controlled?", *IEEE Control Sys Mag*, **25(1)**, pp. 80-83, 2005.

[70] Bonhoeffer S., Coffin J.M. and Nowak M.A. "Human immunodeficiency virus drug therapy and virus load" *J. Virol.*, **71**, pp. 3275-3278, 1997.

[71] Callaway D.S. and Perelson A.S. "HIV-1 infection and low steady state viral loads", *Bull. Math. Biol.*, **64**, pp. 29-64, 2002.

[72] Culshaw R.V. and Ruan S. "A delay-differential equation model of HIV infection of $CD4^+$ T cells", *Mathematical Biosciences*, **165**, pp. 27-39, 2000.

[73] de Souza F.M.C. "Modeling the dynamics of HIV-1 and CD4 and CD8 lymphocytes", *IEEE Eng. Med. and Bio.*, Jan/Feb, pp. 21-24, 1999.

[74] Ding A.A. and Wu H. "Relationships between antiviral treatment effects and biphasic viral decay rates in modeling HIV dynamics", *Math. Bioscie.*, **160**, pp. 63-82. 1999.

[75] Gumel A.B., Shivakumar P.N. and Sahai B.M. "A mathematical model for the dynamics of HIV-1 during the typical course of infection", *Nonlin. Anal.*, **47**, pp. 1773-1783, 2001.

[76] Hraba T. and J. Dolezal, "A mathematical model and $CD4^+$ lymphocyte dynamics in HIV infection." *Emerging Infectious Diseases*, **2(4)**, pp. 299-305, 1996.

[77] Kirschner D. "Using mathematics to understand HIV immune dynamics", *AMS Notices,* **43(2)**, pp. 191-202, 1996.

[78] Kirschner D. and Perelson A.S. "A model for the immune system response to HIV: AZT treatment studies", in: *Mathematical Population Dynamics: Analysis of Heterogeneity*, **1**, pp. 295-310, 1995. Eds. Arino O., Axelrod D., Kimmel M. and Langlais M. Wuerz Publishing, Winnepeg.

[79] Kirschner D. and Webb G.F. "Resistance, remission, and qualitative differences in HIV chemotherapy", *Emerging Infectious Diseases,* **3(3)**, pp. 273-283, 1997.

[80] Kramer I., "Modeling the dynamical impact of HIV on the immune system: viral clearance, infection, and AIDS," *Math. and Comp. Mod.*, **29**, pp. 95-112, 1999.

[81] Murray J.M., Kuafmann G., Kelleher A.D. and Cooper D.A., "A model of primary HIV-1 infection," *Math. Biosci.*, **154**, pp. 57-85, 1998.

[82] Nelson P.W., Murray J.D. and Perelson A.S., "A model of HIV-1 pathogenesis that includes an intracellular delay," *Math. Bioscie.*, **163**, pp. 201-215, 2000.

[83] Nelson P.W. and Perelson A.S. "Mathematical analysis of delay differential equation models of HIV-1 infection", *Math. Biosci.*, **179**, pp. 73-94, 2002.

[84] Nowak M.A. and May R.M. *Virus Dynamics: mathematical principles of immunology and virology,* Oxford University Press. New York, 2000.

[85] Perelson A.S. and Nelson P.W. "Mathematical analysis of HIV-1 dynamics in vivo", *SIAM Rev*, **41(1)**, pp. 3-44, 1999.

[86] Tan W-Y. and Wu H. "Stochastic modeling of the dynamics of $CD4^+$ T-cell infection by HIV and some Monte Carlo studies", *Math. Biosci.*, **147,** pp. 173-205, 1998.

[87] Wodarz D. "Helper-dependent vs. helper-independent CTL responses in HIV infection: implications for drug therapy and resistance", *J. Theor. Biol.*, **213**, pp. 447-459, 2001.

[88] De Boer R.J., Mohri H., Ho D.D. and Perelson A.S. "Estimating average cellular turnover from 5-bromo-2'-deoxyuridine (BrdU) measurements." *Proc. Royal Soc. London B*, **270**, pp. 849-858, 2003.

[89] Gray C.M., Williamson C., Bredell H, Puren A., Filter R., Xia X., *et al.* "Viral dynamics, CD4 counts and human leukocyte antigen types in subtype human immunodeficiency virus type-1 infected individuals from Southern Africa: significance for vaccine trials." *AIDS Research and Human Retroviruses*, **21(4)**, pp. 285-291, 2005.

[90] Ho. D.D., Neuwmann A.U., Perelson A.S., *et al.* "Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection," *Nature*, **373**, pp. 123-126(abstract), 1995.

[91] Mittler J.E., Markowitz M., Ho D.D. and Perelson A.S. "Improved estimates for HIV-1 clearance rate and intracellular delay". *AIDS.* **13** pp. 1415-1417, 1999.

[92] Mohri H., Perelson A.S., Tung K., Ribeiro R.M., *et al.* "Increased turnover of T lymphocytes in HIV-1 infection and its reduction by antiretroviral therapy," *J. Exp. Med.*, **194(9)**, pp. 1277-1287, 2001.

[93] Ramratnam B., Bonhoeffer S., Mittler J.E., Zhang L., Boden D., Hurley A., *et al.* "The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy", *Nature Med.*, **6(1)**, pp. 82-85, 2000.

[94] Wang, L., J. Chen, B. Gelman, R. Konig and M. Cloyd. "A novel mechanisms of CD4 lymphocyte depletion involves effects of HIV on resting lymphocytes: induction of lymph node homing and apoptosis upon secondary signaling through homing receptors." *J. Immunol.*, **162**, pp. 268-276, 1999.

[95] Hoetelmans R.M.W., Reijers M.H., Weverling G.J., *et al.* "The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy", *AIDS*; **12**, pp. 111-115, 1998.

[96] Hraba T., Dolezal J. and Celikovsky S. "Model based analysis of $CD4^+$ lymphocyte dynamics in HIV infected individuals," *Immunobiology*, **181** , pp. 108-118, 1990.

[97] Huang Y.,Rosenkranz S.L. and Wu H., "Modeling HIV dynamics and antiviral response with consideration of time-varying drug exposures, adherence and phenotypic sensitivity", *Math. Biosciences* **184** pp. 165-186, 2003.

[98] Little S.J., McLean A.R., Spina C.A., Richman D.D. and Havlir D.V., "Viral dynamics of acute HIV-1 infection," *J. Exp. Med.*, **190(6)**, pp. 841-850, 1999.

[99] Perelson A.S., Kirschner D. and De Boer R. "Dynamics of HIV infection of $CD4^+$ T cells," *Mathematical Biosciences*, **114**, pp. 81-125, 1993.

[100] Perelson A.S. Neumann A.W., Markowitz M. and *et al.*, "HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time", *Science Mag. (online abstract)*, **271**, pp. 1582-1586, 1996.

[101] University of Pretoria, "HIV/AIDS educational CD-ROM", Available [online]: http://www.be.up.co.za, 2002.

[102] Jeffrey A.M., Xia X. and Craig I.K. "A model based analysis of anti-CD4 therapy as adjuvant to HAART interruption," *16th IFAC World Congress*, Prague, Czech Republic, 04-09 July 2005a.

[103] Jeffrey A.M., Xia X. and Craig I.K."Drug dosage level design to maximize the benefits of therapy", *Proc. IEEE* 7^{th} *Africon Conf.*, Gaborone, Botswana, 15-17 September 2004.

[104] Jeffrey A.M., Xia X. and Craig I.K. "On attaining maximal and durable suppression of the viral load ," *1st African Control Conference AFCON*, Cape Town, South Africa, 03-05 December 2003c.

[105] Jeffrey A.M., Xia X. and Craig I.K. "Identifiability of an extended HIV model", *Proc.* 5^{th} *IFAC Symp. Modelling and Control in Biomedical Systems*, Melbourne, Australia, pp. 507-512, 21-23 August 2003a.

[106] Jeffrey A.M. and Xia X. "Estimating the viral load response time after HIV chemotherapy", *Proc. IEEE* 6^{th} *Africon Conf.*, George, South Africa, **1**, pp. 77-80, 02-04 October 2002.

[107] Jeffrey A.M., Xia X. and Craig I.K. "Controllability analysis of the chemotherapy of HIV," *15th IFAC World Congress*, Barcelona, Spain, 21-26 July 2002.

[108] ATIS : Department of Health and Human Services. *Glossary of HIV/AIDS-Related Terms* 4th Edition [online] www.hivatis.org, September 2002.

[109] AIDS.ORG "FactSheets: HIV life cycle," *AIDS.ORG*, available [online] http://www.aids.org/factSheets/400-HIV-Life-Cycle.html Accessed December 14, 2005.

[110] Jennings C., *Understanding and preventing AIDS: a book for everyone*, Health Alert Press, Cambridge, MA, 1996. Available [online]: http://www.aproposinc.com/hap/toc_long.htm

[111] Wodarz D., Lloyd A.L., Jansen V.A.A., and Nowak M.A. "Dynamics of macrophage and T cell infection by HIV", *J. Theor. Biol.*, **196**, pp. 101-113, 1999.

[112] Igarashi T., Brown C.R., Endo Y., Buckler-White A., *et al.* "Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of $CD4^+$ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans," *Proc. Natl. Acad. Scie.*, **98(2)**, pp. 658-663, 2001.

[113] Muller V., Maree A.F.M. and De Boer R.J. "Release of virus from lymphoid tissue affects human immunodeficiency virus type 1 and hepatitis C virus kinetics in the blood", *J. Virol.*, **75(6)**, pp. 2597-2603, 2001.

[114] Hlavacek W.S., Stilianakis N.I., Notermans D.W., Danner S.A. and Perelson A.S. "Influence of follicular dendritic cells on decay of HIV during antiretroviral therapy", *PNAS*, **97(20)**, pp. 10966-10971, 2000.

[115] Hunt R. "Virology - chapter seven: human immunodeficiency virus and AIDS", *Microbiology and Immunology On-line* University of South Carolina, School of Medicine [online]: http://www.med.sc.edu:85/lecture/hiv2000.htm Accessed 04 November 2005.

[116] De Boer R.J., Mohri H., Ho D.D. and Perelson A.S. "Turnover rates of B cells, T cells, and NK cells in simian immunodeficiency virus-infected and uninfected rhesus macaques1." *The Journal of Immunology*, 2003, **170**, pp. 2479-2487, 2003.

[117] Clarke J.R., White N.C. and Webber J.N. "HIV compartmentalization: pathogenesis and clinical implications", *AIDS Rev.*, **2**, pp. 15-22, 2000.

[118] Bonhoeffer S. and Nowak M.A. "Pre-existence and emergence of drug resistance in HIV-1 infection", *Proc. Roy. Soc. London B*, **264**, pp. 631-637, 1997.

[119] Bangsberg D.R., Charlebois E.D., Grant R.M., Holodniy M., Deeks S.G., *et al.* "High levels of adherence do not prevent accumulation of HIV drug resistant mutants," *AIDS*, **17**, pp. 1925-1932, 2003.

[120] Fumero E., Garcia F. and Gatell J.M. "Immunosuppressive drugs as an adjuvant to HIV treatment", *J. Antimicrobial Chemo.*, **53**, pp. 415-417, 2004.

[121] Lane H.C. "Immunopathogenesis and immune reconstitution", *Medscape*, 2002, [online] http://www.medscape.com/viewarticle/440466. Accessed 14 Nov. 2002.

[122] Cepeda J.A. and Wilks D. "Excess peripheral neuropathy in patients treated with hydroxyurea plus didanosine and stavudine for HIV infection". *AIDS*, **14(3)** pp. 332-333, 2000.

[123] Havlir D.V., Gilbert P.B., Bennett K., *et al.* "Effects of treatment intensification with hydroxyurea in HIV infected patients with virologic suppression". *AIDS*, **15(11)**, pp. 1379-1388, 2001.

[124] Zala C., Salomon H., Ochoa C., *et al.* "Higher rate of toxicity with no increased efficacy when hydroxyurea is added to a regimen of stavudine plus didanosine and nevirapine in primary HIV infection". *J Acquired Immune Deficiency Syndrome*, **29(4)**, pp. 368-373, 2002.

[125] De Boer R.J. and Boucher C.A.B. "Anti-CD4 therapy for AIDS suggested by mathematical models", *Proc. Biol. Scie.*, **263(1372)**, pp. 899-905, 1996.

[126] Pirmohamed M. and Back D.J. "The pharmacogenomics of HIV therapy," *Pharmacogen. J.*, **1**, pp. 243-253, 2001.

[127] Lori F. and Lisziewicz J. "Structured treatment interruptions for the management of HIV infection", *JAMA*, **286(23)**, pp. 2981-2987, 2001.

[128] Dorman K., Kaplan A., Lange K. and Sinsheimer J. "Mutation takes no vacation: can structured treatment interruptions increase the risk of drug resistant HIV-1?" *J Acquir Immune Defic Syndr*, **24(5)**, pp. 398-402, 2000.

[129] Martinez-Picado J., Morales-Lopetegi K., Wrin T., Prado J.G., *et al.* "Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions", *AIDS*, **16**, pp. 895-899, 2002.

[130] Metzner K.J., Bonhoeffer S., Fischer M., Karanicolas R., Weber R., Hirschel B., *et al.* "Detection of minor populations of drug-resistant-viruses in patients undergoing structured treatment interruptions". *Antiviral. Ther.*, **7**, pp. 73, 2002.

[131] Schweighardt B., Ortiz G.M., Grant R.M., Wellons M., *et al.* "Emergence of drug-resistant HIV-1 mutants in patients undergoing structured treatment interruptions" *AIDS*, **16(17)**, pp. 2342-2344, 2002.

[132] Dybul M., Chun T-W., Yoder C., Hidalgo B., and *et al.* "Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic and toxicity parameters". *Proc. Natl Acad Sci - USA*, **98(26)**, pp. 15161-15166, 2001.

[133] NIH News Release, "The SMART Way to Fight AIDS", *http* : *//www.nih.gov/news/pr/jan*2002/*niaid* − 10.*html*, 10 January 2002.

[134] Bonhoeffer S., Rembiszewski M., Ortiz G.M. and Nixon D.F. "Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection", *AIDS*, **14**, pp. 2313-2322, 2000.

[135] Davey R.T. Jr., Bhat N., Yoder C., Chun T-W., Metcalf J.A., Dewar R., *et al.* "HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression", *PNAS*, **96(26)**, pp. 15109-15114, 1999.

[136] Fagard C., Oxenius A., Günthard H., Garcia F., *et al.* "A prospective trial of structured treatment interruptions in human immunodeficiency virus infection" *Arch. Intern. Med.*, **163(10)**, pp. 1220-1226, 2003.

[137] Fischer M., Hafner R., Schneider C., Trkola A., *et al.* "HIV RNA in plasma rebounds within days during structured treatment interruptions" *AIDS*, **17(2)**, pp. 195-199, 2003.

[138] Frost S.D.W., Martinez-Picado J., Ruiz L., Clotet B. and Brown A.J.L. "Viral dynamics during structured treatment interruptions of chronic human immunodeficiency virus type 1 infection", *J. Virology*, vol. 76(3), pp. 968-979, 2002.

[139] Garcia F., Plana M., Ortiz G.M., Bonhoeffer S., *et al.* "The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection", *AIDS*, **15(9)**, pp. F29-F40, 2001.

[140] Hirschel B., Faggard C., Oxenius A., *et al.* "A Prospective Trial of Treatment Interruption in HIV Infection", *Programmes and abstracts of the 9th Conference on Opportunist Infections* (Seattle, USA), Feb. 24-28, 2002.

[141] Lori F., Foli A., Maserati R., Siminari E., *et al.* "Control of HIV during a structured treatment interruption in chronically infected individuals with vigorous T cell responses", *HIV Clin. Trials*, **3**, pp. 115-124, 2002.

[142] Ortiz G.M., Wellons M., Brancato J., Vo H.T.T., *et al.* "Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects", *PNAS*, **98(23)**, pp. 13288-13293, 2001.

[143] Oxenius A., Price D.A., Günthard H.F., Dawson S.J., *et al.* "Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection", *Proc. Natl. Acad. Sci*, **99(21)**, pp. 13747-13752, 2002.

[144] Oxenius A., McLean A., Fischer M., Price D.A., *et al.* "HIV-specific CD8+ T cell responses do not predict viral growth and clearance rates during structured intermittent antiretroviral therapy", *J Virol.*, **76**, pp. 10169-10175, 2002b.

[145] Ruiz L., Carcelian G., Martnez-Picado J., Frost S., *et al.* "HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection", *AIDS*, **15(9)**, pp. 19-27, 2001.

[146] Stellbrink H.J., van Lunzen J., Westby M., OSullivan E., Schneider C., Adam A., *et al.* "Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial)". *AIDS*, **16**, pp. 1479-1487, 2002.

[147] Katlama C., Dominguez S., Duvivier C., Delaugerre C., *et al.* "Long-term benefit of treatment interruption in salvage therapy," *Proc. 10th Conference on Retroviruses and Opportunistic Infections*, Abstract 68, 2003.

[148] Miller V., Sabin C., Hertogs K., Bloor S., Martinez-Picado J., DAquila R., *et al.* "Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure". *AIDS*, **14**, pp. 2857-2867, 2000.

[149] Mussini C., Bugarini R., Perno C., *et al.* "Virological and immunological effects of discontinuation of antiretroviral therapy in patients with virological failure", *Programmes and abstracts of the 9th Conference on Opportunist Infections* (Seattle, USA), Feb. 24-28, 2002.

[150] Ruiz L., Martnez-Picado J., Romeu J., Paredes R., *et al.* "Structured treatment interruptions in chronically HIV-1 infected patients after long-term viral suppression", *AIDS*, **14(4)**, pp. 397-403, 2000.

[151] Bajaria S.H., Webb G. and Kirschner D.E. "Predicting differential responses to structured treatment interruptions during HAART," *Bull. Math. Bio.*, **66**, pp. 1093-1118, 2004.

[152] Hatano H., Vogel S., Yoder C., Metcalf J., *et al.* "Pre-HAART HIV burden approximates post-HAART viral levels following interruption of therapy in patients with sustained viral suppression" *AIDS*, **14(10)**, pp. 1357-1363, 2000.

[153] Blankson J., Siliciano J., Finzi D., Quinn T., Gallant J. and Siliciano R. "Rapid initial decay of latently infected cells following re-initiation of HAART in chronically HIV-1 infected patients with treatment interruptions," *Abstracts from the 9th Conference on Retroviruses and Opportunistic Infections*, Abstract 491-M, 2002.

[154] Neumann A., R. Tubiana, V. Calvez, C. Robert, T.-S. Li, H. Agut, B. Autran, C. Katlama and The Comet Study Group. "HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment," *AIDS* **13**, pp. 677683, 1999.

[155] Carcelain G., Tubiana R., Samri A., Calvez V., *et al.* "Transient mobilization of human immunodeficiency virus (HIV)- specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection," *J Virology*, **75**, pp. 234-241, 2001.

[156] Papasavvas E., Grant R., Sun J., Mackiewicz A., Pistilli M., Gallo C., Kostman J., Mounzer K., Shull J. and Montaner L. "Lack of persistent drug-resistant mutations evaluated within and between treatment interruptions in chronically HIV-1-infected patients", *AIDS*, **17**, pp. 2337-2343, 2003.

[157] Dybul M., *et al.* "A randomized controlled trial of long cycle structured intermittent versus continuous ARV therapy for chronic HIV infection," *Abstracts from the 10th Conference on Retroviruses and Opportunistic Infections*, Abstract 681b.

[158] Poulton, M., Sabin C. and Fischer M. "Immunological changes during treatment interruptions: risk factors and clinical sequelae." *AIDS*, **17**, pp. 126128, 2003.

[159] Blankson J., Gallant J., Quinn T., Bartlett J. and Siliciano R. "Loss of HIV-1 specific immunity during treatment interruption in 2 chronically infected patients," *JAMA*, **288**, pp. 162-164, 2002.

[160] Perelson A.S. "Modelling the interaction of the immune system with HIV," in *Mathematical and Statistical Approaches to AIDS Epidemiology*, (Lect. Notes Biomath.), C. Castillo-Chavez, Ed., Springer Verlag, New York, **83**, pp. 350-370, 1989.

[161] Chun T-W., Carruth L., Finzi D., Xhen X., *et al.* "Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection". *Nature*, **387**, pp. 183-188, 1997.

[162] Perelson, A.S., Essunger P., Cao Y., Vesanen M., Hurley A., Saksela K., Markowitz M. and Ho D.D. "Decay characteristics of HIV-1 infected compartments during combination therapy", *Nature*, **387**, pp. 188-191, 1997.

[163] Perelson A.S., Essunger P., Markowitz M. and Ho D.D., "How long should treatment be given if we had an antiretroviral regimen that completely blocked HIV replication?", *XIth Intl. Conf. AIDS Abstracts*, 1996.

[164] Filter R.A. "Dynamic HIV/AIDS parameter estimation with applications", *MEng(Electronic Eng) Dissertation*, University of Pretoria, Pretoria, South Africa. 2005.

[165] Haase A.T., Henry K., Zupancic M., Sedgewick G., Faust R., *et al.* "Quantitative image analysis of HIV-1 infection in lymphoid tissue", *Science*, **274**, pp. 985-989, 1996.

[166] Dewhurst S., da Cruz R.L.W. and Whetter L. "Pathogenesis and treatment of HIV-1 infection: recent developments (Y2K update)", *Front. Biosci.*, **5**, pp. 30-49. 2001.

[167] Douek D.C., McFarland R.D., Keiser P.H., *et al.* "Changes in thymic function with the age and during treatment of HIV infection", *Nature*, **396**, pp. 690-695, 1998.

[168] Stilianakis N.I., Dietz K. and Schenzle D. "Analysis of a model of the pathogenesis of AIDS" *Math. Biosci.*, **145**, pp. 27-46, 1997.

[169] McLeod G.X. and Hammer S.M. "Zidovudine: 5 years later," *Ann. Intern. Med.*, **117**, pp. 487-501, 1992.

[170] Nise N.S. *Control Systems Engineering*. John Wiley and Sons, New York, 2000.

[171] Muller V., Maree A.F.M. and De Boer R.J. "Small variations in multiple parameters account for wide variations in HIV-1 set-points: a novel modelling approach ," *Proc. Royal Soc. Lond. B. Biol. Sci.*, **268**, pp. 235-242, 2001.

[172] Rizzardi G.P., De Boer R.J., Hoover S., Tambussi G., *et al.* "Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA", *J. Clin. Investigation.* **105(6)**, pp. 777-782, 2000.

[173] Hoetelmans R.M.W. "Clinical pharmacokinetics of antiretroviral drugs", *AIDS Rev*; **1**, pp. 167-178, 1999.

[174] De Boer R.J. and Perelson A.S. "Target cell limited and immune control models of HIV infection: a comparison", *J. Theor. Biol.*, **190**, pp. 201-214, 1998.

[175] Skogestad S. and Postlethwaite I. *Multivariable Feedback Control : Analysis and Design*, John Wiley & Sons, Chichester, England, 1996.

[176] Ramratnam B., Bonhoeffer S., Binley J., Hurley A., *et al.* "Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis", *Lancet*, **354(20)**, pp. 1782-1785, 1999.

[177] Becker S.L. and Hoetelmas R.M.W. "Exploiting pharmacokinetics to optimize antiretroviral therapy", *Medscape's CME activity,* [online] *http* : *//www.medscape.com/viewprogram/*703. Accessed 11/7/2002.

[178] Lindpainter K., "Pharmacogenetics and the future of medical practice: conceptual considerations," *Pharmacogen. J.*, **1**, pp. 23-26, 2001.

[179] Wei X., Ghosh S.K., Taylor M.E., Johnson V.A., *et al.* . "Viral dynamics in HIV-1 infection," *Nature.* **273**, pp. 117-121, 1995.

[180] Jelliffe R.W., "Optimal design of drug dosage regimens" *Ann. Int. Conf. IEEE in Med. and Biol. Society*, **13(5)**, pp. 2164-2165, 1991.

[181] Mahfouf M., Linkens D.A. and Xue D, "A new generic approach to model reduction for complex physiologically based drug models," *Control Eng. Pract.*, **10**, pp. 67-81, 2002.

[182] Ferguson N.M., Fraser C. and Anderson R.M. "Viral dynamics and anti-viral pharmacodynamics: rethinking in vitro measures of drug potency", *Trends in Pharm. Scie.*, **22(2)**, pp. 97-100, 2001.

[183] Joshi A.S., Barrett J.S., Fiske W.D., *et al*, "Population pharmacokinetics of efavirenzin phase II studies and relationship with efficacy", *Prog. and abstr.* 30^{th} *ICAAC,* San Francisco, USA, 26—29 Sept. 1999.

[184] Gerber J.G. and Acosta E.P. "Therapeutic drug monitoring in the treatment of HIV infection", *J. Clin. Virol.*, **27**, pp. 117-128, 2003.

[185] Mathworks, "Model predictive toolbox - users guide", 2006.

[186] Maciejowski J.M. *Predictive Control with Constraints,* Prentice Hall, Harlow, England, 2002.

[187] Camacho E.F. and Bordons C. *Model Predictive Control,* Springer-Verlag. London, 1999.

[188] Goodwin G.C., Graebe S.F. and Salgado M.E. *Control System Design,* Prentice Hall, Upper Saddle River, New Jersey, 2001.

[189] Gallant J.E. and Squires K.E. "Non-nucleoside reverse transcriptase inhibitors in the treatment of HIV: focus on efficacy", *Medscape's CME activity,* Available [online]: http://www.medscape.com/viewprogram/2853. Accessed 10 June 2004.

Appendix A

Parameter Estimates

Table A.1: Parameter estimates for the latently infected model : Set 1.

Parameter	Value
s_T	10 mm^{-3} day^{-1}
p	0.03 day^{-1}
T_{max}	1500 mm^{-3}
d_T	0.01 day^{-1}
β_T	7.5×10^{-6} mm^3 day^{-1}
δ_l	0.01 day^{-1}
δ_a	0.5 day^{-1}
k	0.075
q_l	0.05
q_a	0.55
r_T	2000 cell^{-1} day^{-1}
c	5 day^{-1}

[84, 85, 50, 46]

Table A.2: Parameter estimates for the latently infected model : Set 2.

Parameter	Value
s_T	10 mm^{-3} day^{-1}
p	0.03 day^{-1}
T_{max}	1000 mm^{-3}
d_T	0.01 day^{-1}
β_T	4×10^{-5} mm^3 day^{-1}
δ_l	0.01 day^{-1}
δ_a	0.5 day^{-1}
k	0.025
q_l	0.005
q_a	0.55
r_T	240 cell^{-1} day^{-1}
c	5 day^{-1}

Table A.3: Parameter estimates for the latently infected model : Set 3.

Parameter	Value
s_T	10 mm^{-3}day^{-1}
d_T	0.01 day^{-1}
β_T	7.5×10^{-6} mm^{3}day^{-1}
q_l	0.05
q_a	0.8
δ_l	0.01 day^{-1}
δ_a	0.5 day^{-1}
k	0.075
r_T	2000 virions cell^{-1}day^{-1}
c	5 day^{-1}

[85, 50, 84, 7, 90].

Table A.4: Typical parameters estimates for the extended model.

Parameter	Typical Value
$T(0)$	10^6 mL^{-1}
$M(0)$	3×10^4 mL^{-1}
$V(0)$	10 mL^{-1}
s_T	10^4 mL^{-1}day^{-1}
d_T	0.01 day^{-1}
β_T	4.5×10^{-8} mL day^{-1}
p	0.02 day^{-1}
T_m	10^6 mL^{-1}
q_l	0.005
q_a	0.55
δ_l	0.01 day^{-1}
δ_a	0.5 day^{-1}
k	0.025 day^{-1}
s_M	150 mL^{-1}day^{-1}
d_M	0.005 day^{-1}
β_M	1.75×10^{-8} mL day^{-1}
q_M	1
μ	0.05 day^{-1}
r_T	240 cell^{-1}day^{-1}
r_M	35 cell^{-1}day^{-1}
c	5 day^{-1}
η_{rt}	$[0, 1)$
η_{pi}	$[0, 1)$
α_{rt}	$(0, 1]$
α_{pi}	$(0, 1]$
η_{ps}	$[0, 1)$
η_{da}	$[0, 1]$

[46, 71, 78, 84, 176]